Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Net Margin: 2023-2025

Historic Net Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to -2,737.30%.

  • Entrada Therapeutics' Net Margin fell 266580.00% to -2,737.30% in Q3 2025 from the same period last year, while for Sep 2025 it was -168.32%, marking a year-over-year decrease of 19387.00%. This contributed to the annual value of 31.12% for FY2024, which is 3627.00% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Net Margin is -2,737.30%, which was down 23.77% from -2,211.54% recorded in Q2 2025.
  • Entrada Therapeutics' Net Margin's 5-year high stood at 81.09% during Q3 2023, with a 5-year trough of -2,737.30% in Q3 2025.
  • Over the past 3 years, Entrada Therapeutics' median Net Margin value was -26.62% (recorded in 2023), while the average stood at -464.99%.
  • Its Net Margin has fluctuated over the past 5 years, first spiked by 20,077bps in 2024, then tumbled by 266,580bps in 2025.
  • Over the past 3 years, Entrada Therapeutics' Net Margin (Quarterly) stood at -22.70% in 2023, then skyrocketed by 2,566bps to 2.95% in 2024, then tumbled by 266,580bps to -2,737.30% in 2025.
  • Its Net Margin stands at -2,737.30% for Q3 2025, versus -2,211.54% for Q2 2025 and -84.39% for Q1 2025.